Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 7/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.39 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.39 |
| ▸ | ASPH | Q12797 | 1/20 | 0.39 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4996354 | 0.83 | EGLN3 (0.80) | EGLN3EGLN1EGLN2 | |
| SCHEMBL4992365 | 0.82 | EGLN3 (0.73) | EGLN3EGLN1EGLN2CYP2C19 | |
| SCHEMBL5000271 | 0.80 | EGLN3 (0.78) | EGLN3EGLN1EGLN2 | |
| SCHEMBL4992967 | 0.80 | EGLN3 (0.57) | EGLN3HIF1AEGLN1EGLN2CYP2C19 | |
| SCHEMBL4992707 | 0.79 | EGLN3 (1.00) | EGLN3EGLN1EGLN2CYSLTR2 | |
| SCHEMBL4989389 | 0.79 | EGLN3 (0.77) | EGLN3EGLN1EGLN2 | |
| SCHEMBL4738060 | 0.76 | EGLN3 (0.65) | EGLN3EGLN1CYP2C19 | |
| SCHEMBL4992689 | 0.75 | EGLN3 (0.63) | EGLN3EGLN1CYP2C19 | |
| SCHEMBL4996324 | 0.73 | EGLN3 (0.87) | EGLN3EGLN1EGLN2CYSLTR2CYP2C19 | |
| SCHEMBL4989342 | 0.73 | EGLN3 (0.66) | EGLN3EGLN1EGLN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | claimed |
| WO-2008089051-A1 | N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | EGLN3 3/4885HIF1A 4/4885EGLN1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.